Skip to main content
Monday, November 16, 2026Nov 16

HIV drug patients’ privacy violated by Gilead, lawsuit claims

In this photo taken July 9, 2015, a man cycles near the headquarters of Gilead Sciences in Foster City, Calif. A bipartisan investigation by U.S. senators finds that the makers of a breakthrough drug for hepatitis C infection put profits before patients in pricing the $1,000-per-pill cure. The report released Tuesday by the Senate Finance Committee concludes that California-based Gilead Sciences was focused on maximizing revenue even as its own analysis showed a lower price would allow more patients to be treated for the liver-wasting disease. (AP Photo/Eric Risberg)
In this photo taken July 9, 2015, a man cycles near the headquarters of Gilead Sciences in Foster City, Calif. A bipartisan investigation by U.S. senators finds that the makers of a breakthrough drug for hepatitis C infection put profits before patients in pricing the $1,000-per-pill cure. The report released Tuesday by the Senate Finance Committee concludes that California-based Gilead Sciences was focused on maximizing revenue even as its own analysis showed a lower price would allow more patients to be treated for the liver-wasting disease. (AP Photo/Eric Risberg)

PHILADELPHIA – A drug company may have violated the privacy of thousands of people who are taking a medicine to prevent them from coming down with HIV.

Gilead Sciences, the biopharmaceutical giant, sent out a mass mailing in mid-April to people on its antiretroviral drugs, Truvada and Descovy. The drugs are used to reduce the risk of HIV infection, a prevention measure called pre-exposure prophylaxis (PrEP).

On Thursday, the AIDS Law Project of Pennsylvania filed a federal class action suit against Gilead. It claims the company illegally compromised the privacy rights of patients by recklessly mailing the inappropriately marked envelopes after promising confidentiality.

The suit demands that Gilead’s HIV Prevention Team immediately stop sending out letters to patients and seeks unspecified monetary damages. It was filed in the Northern District of California. The AIDS Law Project was joined by law firms Berger and Montague and Langer Grogan and Diver.

“We regret that the envelope caused any concerns, and we apologize to anyone affected,” Gilead, which is on the forefront of developing a COVID-19 vaccine, said a statement. “However, we deny the assertions in the complaint and will file our response in a timely manner.”